Abstract:Xinchen Wang, 1 Chen Wei, 1 Wenjun Fan, 1 Lixian Sun, 1 Ying Zhang, 1 Qiyu Sun, 2 Yixiang Liu, 1 Jingyi Liu 1 1 Department of Cardiology, The Affiliated Hospital of Chengde Medical University, The Chengde Institute of Cardiovascular Diseases, Chengde, Hebei, 067000, People's Republic of China; 2 Department of Clinical Laboratory, The Affiliated Hospital of Chengde Medical University, Chengde, Hebei, 067000, People's Republic of China Correspondence: Lixian Sun, Department of Cardiology, The Affiliated Hospital of Chengde Medical University, Chengde, Hebei, 067000, People's Republic of China, Tel +86 314 227 9016, Fax +86 314 227 4895, Email Purpose: The decreased advanced lung cancer inflammation index (ALI), defined as body mass index (BMI) &ast albumin (Alb)/neutrophil-to-lymphocyte ratio (NLR), is an independent prognostic risk factor for overall survival in gastric, lung, and colorectal cancers. This study aimed to investigate the value of ALI in predicting the risk of major adverse cardiovascular events (MACEs) in patients with acute coronary syndrome (ACS). Patients and Methods: A total of 1624 patients with ACS undergoing percutaneous coronary intervention (PCI) were consecutively enrolled between January 2016 and December 2018. Follow-up data were collected at 1, 3, 6, and 12 months and annually thereafter. The primary endpoints were MACEs. All endpoints were defined as all-cause mortality, recurrent angina pectoris, restenosis/intra stent thrombosis, stroke, heart failure, and all-cause bleeding. Results: The MACEs group and non-MACEs group showed significant differences in patients with age > 65 years (28 [50.0%] vs 319 [23.7%]), history of heart failure (16 [28.6%] vs 127 [9.4%]), history of ischemic stroke (14 [25.0%] vs 186 [13.8%]), history of cardiogenic shock (6 [10.71%] vs 16 [1.19%]), left ventricular ejection fraction < 40% (8 [14.29%] vs 33 [2.46%]), and ALI < 343.96 (44 [78.65%] vs 680 [50.60%]) (all p< 0.001). The optimal cut-off value for ALI was 334.96. The area under the curve (AUC) of the 1-, 2-, 3-, and 5-year was 0.560, 0.577, 0.665, and 0.749, respectively. The survival rate was significantly lower in the low ALI group than in the high ALI group (log-rank p< 0.001). Low ALI was an independent risk factor for the long-term prognosis of patients with ACS after PCI, univariate HR: 3.671, 95% CI: 1.938– 6.953, p< 0.001; multivariate HR: 3.009, 95% CI: 1.57– 5.769, p=0.001. Conclusion: ALI score less than 334.96 is an independent prognostic risk factor for patients with ACS undergoing PCI and may be a novel marker for clinical practice. Keywords: acute coronary syndrome, advanced lung cancer inflammation index, prognosis, percutaneous coronary intervention Recent research shows that more than 7 million people are newly diagnosed with acute coronary syndrome (ACS) each year. 1 Although great progress has been made in the diagnosis and treatment of ACSs, such as the development of percutaneous coronary intervention and dual antiplatelet therapy and the high prevalence of coronary computed tomographic angiography, ACS remains the leading cause of death worldwide. 2–5 Accurate assessment of prognostic risk and standard follow-up are widely recognized to be important approaches to improving patient survival. 6 In recent years, research attention has focused on different kinds of inflammatory indices, as a convenient and noninvasive measure for diagnosing and assessing prognostic risks. 7–9 The advanced lung cancer inflammation index (ALI) is a novel index that was firstly reported by Jafri et al in 2013. 10 This index is defined as body mass index (BMI) * albumin (Alb)/neutrophil-to-lymphocyte ratio (NLR). BMI is calculated as the height (m)/ weight (kg)^2. The NLR is involved in inflammation, and both BMI and albumin are associated with systemic nutritional status. Numerous studies have shown that inflammation and nutrient status are correlated with coronary heart disease (CAD). 11 The derived neutrophil-to-lymphocyte ratio is an novel independent predictor of mortality in patients undergoing PCI. 12 In oncology, decreased ALI is an independent prognostic risk factor for overall survival in gastric, lung, and colorectal cancers. 13–15 Our previous study using ALI-based nomograms also showed the diagnostic significance of ALI. 16 However, the ability of ALI to predict the prognostic risk in patients with ACS undergoing PCI remains unknown. Thus, this study aimed to investigate the value of ALI in predicting the risk of MACEs in patients with ACS undergoing PCI. This prospective cohort study was -Abstract Truncated-

Advanced Lung Cancer Inflammation Index for Predicting Prognostic Risk for Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Advanced Lung Cancer Inflammation Index as Predictor of All-Cause Mortality in ST-Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention

Prognostic value of advanced lung cancer inflammation index in heart failure patients: A comprehensive analysis

A novel nutritional inflammation index for predicting mortality in acute ischemic stroke patients: insights into advanced lung cancer inflammation index from the Medical Information Mart for Intensive Care-IV database

Advanced lung cancer inflammation index as a predictor of all-cause and cardiovascular mortality among American hypertensive patients

Advanced lung cancer inflammation index is associated with mortality in critically ill patients with heart failure

Advanced Lung Cancer Inflammation Index, a New Prognostic Score, Predicts Outcome in Patients with Small-Cell Lung Cancer.

Advanced Lung Cancer Inflammation Index Predicts the Outcomes of Patients with Non-Metastatic Gastric Cancer after Radical Surgical Resection

The low advanced lung cancer inflammation index to predict poor prognosis of patients with metastatic non-small cell lung cancer.

The Predictive Significance of the Advanced Lung Cancer Inflammation Index (ALI) in Patients with Melanoma Treated with Immunotherapy as Second-Line Therapy

The relationship between advanced lung cancer inflammation index and high SYNTAX score in patients with non-ST-elevation myocardial infarction

A Low Advanced Lung Cancer Inflammation Index Predicts a Poor Prognosis in Patients With Metastatic Non–Small Cell Lung Cancer

Association between advanced lung cancer inflammation index and all-cause and cardiovascular mortality among stroke patients: NHANES, 1999–2018

Prognostic Value of the Advanced Lung Cancer Inflammation Index in Early-Stage Non-Small Cell Lung Cancer Patients Undergoing Video-Assisted Thoracoscopic Pulmonary Resection.

Clinical significance of the advanced lung cancer inflammation index in gastrointestinal cancer patients: a systematic review and meta-analysis

The Prognostic Value of the Advanced Lung Cancer Inflammation Index in Patients with Gastrointestinal Malignancy

Association of advanced lung cancer inflammation index with all-cause and cardiovascular mortality in US patients with rheumatoid arthritis

ALB-dNLR Score Predicts Mortality in Coronary Artery Disease Patients After Percutaneous Coronary Intervention

Nomograms Based on the Advanced Lung Cancer Inflammation Index for the Prediction of Coronary Artery Disease and Calcification

Advanced Lung Cancer Inflammation Index is a Prognostic Factor of Patients with Small-Cell Lung Cancer Following Surgical Resection

Prognostic Significance of Modified Advanced Lung Cancer Inflammation Index in Patients with Renal Cell Carcinoma Undergoing Laparoscopic Nephrectomy: A Multi-Institutional, Propensity Score Matching Cohort Study